Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 7180950)

1.

Sequential studies of circulating immune complexes in gynecological malignancies.

Poulton TA, Crowther ME, Nineham LJ, Mooney NA, Hay FC.

Am J Reprod Immunol. 1982 Oct;2(5):265-9.

PMID:
7180950
2.

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.

Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A.

Int J Gynecol Cancer. 2009 Aug;19(6):1015-21. doi: 10.1111/IGC.0b013e3181ab597f.

PMID:
19820362
4.

[Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].

Sheng XG, Zhang XL, Fu Z, Li HQ, Li QS, Ma ZF, Li DP, Chen ZY.

Zhonghua Fu Chan Ke Za Zhi. 2007 Jul;42(7):460-3. Chinese.

PMID:
17961335
5.

[Modified method for determining circulating immune complexes in the complement fixation test with polyethylene glycol precipitate].

Shoĭbonov BB, Buianova SN, Petrova VD, Fedorov AA, Borgolov VM, Soniev VM, Zinchenko AA.

Klin Lab Diagn. 2007 May;(5):29-35. Russian.

PMID:
17665618
7.

Final report on the safety assessment of Triethylene Glycol and PEG-4.

[No authors listed]

Int J Toxicol. 2006;25 Suppl 2:121-38. Review.

PMID:
17090481
8.

Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma.

Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Tono N, Fassina G, Cavalletto L, Gatta A, Chemello L.

Int J Cancer. 2006 Aug 15;119(4):735-40.

PMID:
16550605
9.

The presence and structure of circulating immune complexes in patients with prostate tumors.

Gołda R, Wolski Z, Wyszomirska-Gołda M, Madaliński K, Michałkiewicz J.

Med Sci Monit. 2004 Mar;10(3):CR123-7. Epub 2004 Mar 1.

PMID:
14976452
10.

Serum tumor markers in the management of ovarian, endometrial and cervical cancer.

Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR.

Biomed Pharmacother. 2004 Jan;58(1):24-38. Review.

PMID:
14739059
11.

[Cancer antigen CA 125 in ovarian cancer].

Debniak J, Stukan M, Pietrzak-Stukan M, Klasa-Mazurkiewicz D.

Ginekol Pol. 2003 Sep;74(9):701-9. Polish.

PMID:
14674111
12.

Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.

Merdan T, Callahan J, Petersen H, Kunath K, Bakowsky U, Kopecková P, Kissel T, Kopecek J.

Bioconjug Chem. 2003 Sep-Oct;14(5):989-96.

PMID:
13129403
13.

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay.

Schultes BC, Whiteside TL.

J Immunol Methods. 2003 Aug;279(1-2):1-15.

PMID:
12969543
14.

A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.

Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA.

Cancer. 2003 Jul 1;98(1):94-9.

15.

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.

Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins RV, DePriest PD, Ueland FR, Kryscio RJ, Whitley RJ, Nagell Jv.

Gynecol Oncol. 2003 May;89(2):233-5.

PMID:
12713985
16.

Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.

Murphy KT, Rotmensch J, Yamada SD, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. Review.

PMID:
12654437
17.

Comparison of serum vascular endothelial growth levels between patients with and without ovarian malignancies.

Dehaven K, Taylor DD, Gercel-Taylor C.

Int J Gynecol Cancer. 2002 Nov-Dec;12(6):715-9.

PMID:
12445248
18.

Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.

Odunsi K, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S.

Am J Obstet Gynecol. 2002 Sep;187(3):575-80.

PMID:
12237630
19.

The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.

Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR.

Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82.

PMID:
11520365
20.

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.

Riisbro R, Stephens RW, Brünner N, Christensen IJ, Nielsen HJ, Heilmann L, von Tempelhoff GF.

Gynecol Oncol. 2001 Sep;82(3):523-31.

PMID:
11520150
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk